Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

Inclusion Criteria: * Primary acute myeloid leukemia (AML) * First complete remission (CR) with high risk features as defined by: failure to achieve remission by day 21 after induction chemotherapy, or the presence of chromosomal abnormalities involving any of the following: -5/de (5q), -7/del(7q), inversion 3q, abnormalities of 11q23, 20q, 21q, del(9q), translocation 6;9, translocation 9;22, abnormalities of 17p, or complex karyotype with \> or = 3 abnormalities. Complete remission is defined as \< 5% blasts in the marrow. * Second CR or subsequent in remission * Refractory or relapsed disease with absolute peripheral blood blasts \< 2000/mcL * Secondary AML in remission or relapse * Chronic myelogenous leukemia (CML) in accelerated or blast phase * Accelerated phase is defined by any one of the following: * Blasts 10% to 19% of peripheral blood white cells or bone marrow cells * Peripheral blood basophils at least 20% * Persistent thrombocytopenia (\<100 x 10\^9/L) unrelated to therapy, or persistent thrombocytosis (\>1000 x 10\^9/L) unresponsive to therapy * Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy * Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase CML) * Resistance to tyrosine kinase inhibitors (imatinib or other) defined as no complete cytogenetic res…